JP2022534680A5 - - Google Patents

Info

Publication number
JP2022534680A5
JP2022534680A5 JP2021568274A JP2021568274A JP2022534680A5 JP 2022534680 A5 JP2022534680 A5 JP 2022534680A5 JP 2021568274 A JP2021568274 A JP 2021568274A JP 2021568274 A JP2021568274 A JP 2021568274A JP 2022534680 A5 JP2022534680 A5 JP 2022534680A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021568274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534680A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/090600 external-priority patent/WO2020228824A1/en
Publication of JP2022534680A publication Critical patent/JP2022534680A/ja
Publication of JP2022534680A5 publication Critical patent/JP2022534680A5/ja
Ceased legal-status Critical Current

Links

JP2021568274A 2019-05-16 2020-05-15 Cd4結合部分を含む免疫細胞受容体 Ceased JP2022534680A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019087260 2019-05-16
CNPCT/CN2019/087260 2019-05-16
PCT/CN2020/090600 WO2020228824A1 (en) 2019-05-16 2020-05-15 Immune cell receptors comprsing cd4 binding moieties

Publications (2)

Publication Number Publication Date
JP2022534680A JP2022534680A (ja) 2022-08-03
JP2022534680A5 true JP2022534680A5 (enExample) 2023-05-22

Family

ID=73289800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568290A Withdrawn JP2022533621A (ja) 2019-05-16 2020-05-15 認識分子を含む操作された免疫細胞
JP2021568274A Ceased JP2022534680A (ja) 2019-05-16 2020-05-15 Cd4結合部分を含む免疫細胞受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568290A Withdrawn JP2022533621A (ja) 2019-05-16 2020-05-15 認識分子を含む操作された免疫細胞

Country Status (8)

Country Link
US (2) US20220241330A1 (enExample)
EP (2) EP3969572A4 (enExample)
JP (2) JP2022533621A (enExample)
KR (2) KR20220009966A (enExample)
CN (3) CN113840912A (enExample)
AU (2) AU2020275049A1 (enExample)
SG (2) SG11202112536UA (enExample)
WO (2) WO2020228825A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
US20240050474A1 (en) * 2021-02-09 2024-02-15 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
GB202105682D0 (en) * 2021-04-21 2021-06-02 Imp College Innovations Ltd Chimeric antigen receptor (CAR)-T cells
GB202105684D0 (en) * 2021-04-21 2021-06-02 Imperial College Innovations Ltd Chimeric antigen receptor (CAR)-T cells
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
CN115819622A (zh) * 2022-09-26 2023-03-21 湖南省人民医院(湖南师范大学附属第一医院) 针对b系白血病或淋巴瘤的双靶点car结构及药物组合物
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
CN116836284A (zh) * 2023-04-21 2023-10-03 浙江正熙生物技术有限公司 一种抗人cd4抗体及其制备方法和应用
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025068899A1 (en) * 2023-09-25 2025-04-03 Janssen Biotech, Inc. Compositions and methods for the generation of engineered, and or engineerable, cells
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2026032970A1 (en) 2024-08-07 2026-02-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cd4-specific chimeric antigen receptor and methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594784A (en) * 2005-08-18 2013-06-28 Genmab As Therapy with CD4 binding peptides and radiation
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104822705B (zh) * 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
WO2017177175A1 (en) * 2016-04-07 2017-10-12 The George Washington University Methods and compositions targeting retroviral latency
AU2017312887A1 (en) * 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
WO2019020733A1 (en) * 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템

Similar Documents

Publication Publication Date Title
JP2021524264A5 (enExample)
JP2025028239A5 (enExample)
JP2022113880A5 (enExample)
JP2025065142A5 (enExample)
JP2020114264A5 (enExample)
JP2023527049A5 (enExample)
JP2021087455A5 (enExample)
JP2021500881A5 (enExample)
JP2024502632A5 (enExample)
JP2020533958A5 (enExample)
JP2018535701A5 (enExample)
JP2022508942A5 (enExample)
JP2022501043A5 (enExample)
JP2020517295A5 (enExample)
JP2021525524A5 (enExample)
JP2024527557A5 (enExample)
JP2020513829A5 (enExample)
TW202246330A (zh) 改良的雙特異性多肽分子
JP2020525536A5 (enExample)
JP2021532742A5 (enExample)
JP2020511136A5 (enExample)
JP2018508219A5 (enExample)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2018526028A5 (enExample)
JP2017524367A5 (enExample)